Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc.
The acquisition involves all issued and outstanding common shares of Repare Therapeutics Inc.
The approval was granted at a special meeting of shareholders held on January 16, 2026.
Approval of Shareholders
99.76% of shareholders approved the acquisition at the special meeting.
Compensation Approval
Shareholders approved the compensation to be paid to named executive officers based on the arrangement.
Liquidation Authorization
In case of termination, shareholders approved voluntary liquidation and appointment of a liquidator.
- The completion of the acquisition is subject to the approval of the Superior Court of Québec and other customary closing conditions.
- Assuming all conditions are met, the acquisition is expected to be completed around January 28, 2026.
Repare Therapeutics Inc.'s shareholders' approval marks a significant step towards the acquisition by XenoTherapeutics, Inc. Once finalized, the transaction is expected to reshape the future of both entities.